← USPTO Patent Grants

Androgen receptor PROTACS

Grant US12577231B2 Kind: B2 Mar 17, 2026

Assignee

GlaxoSmithKline Intellectual Property Development Limited

Inventors

Christopher Patrick Tinworth, Laura Trulli

Abstract

Certain Androgen receptor PROTAC (PROteolysis TArgeting Chimera) compounds contain a series of 2,4-dioxotetrahydropyrimidinyl derivatives that bind cereblon. The PROTAC compounds may be viewed as being comprised of an androgen receptor binding moieties, a linker and a cereblon binding moiety or degron. Medical uses of these PROTAC compounds are also disclosed.

CPC Classifications

C07D 401/14 C07D 405/14 C07D 471/04 C07D 487/04 A61P 35/00

Filing Date

2025-06-30

Application No.

19254759

Claims

28